A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness ...
Sep 24, 2012
0
0
New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.
Jan 19, 2012
0
0
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies ...
Jun 1, 2011
0
0
New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Sep 29, 2012
0
0
Adding lung cancer drugs to targeted melanoma treatment could increase survival for certain patients, according to research published in Cancer Discovery today.
Feb 12, 2013
0
0
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...
Apr 22, 2013
0
0
Scientists at the Universities of Aberdeen and Dundee have established a foot in the door in finding new, precision treatments for patients with oesophageal cancer, one of the hardest forms of the disease to treat.
Jun 15, 2017
0
2
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...
Sep 5, 2013
0
0
(Medical Xpress)—For many patients with non-small-cell lung carcinoma (NSCLC), tumorigenesis is fueled by mutations that hyperactivate the epidermal growth factor receptor (EGFR) signaling protein. These individuals may ...
Feb 15, 2013
0
0
The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor ...
May 18, 2017
0
5
Gefitinib INN ( /ɡɛˈfɪtɨnɪb/), trade name Iressa, is a drug used in the treatment of certain types of cancer, particularly those with mutated and overactive EGFR. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. It is marketed by AstraZeneca and Teva.
This text uses material from Wikipedia, licensed under CC BY-SA
